These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28652236)

  • 21. Bacterial adhesion and host cell factors leading to effector protein injection by type III secretion system.
    Bohn E; Sonnabend M; Klein K; Autenrieth IB
    Int J Med Microbiol; 2019 Jul; 309(5):344-350. PubMed ID: 31178419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type 3 secretion system as an anti-Pseudomonal target.
    Horna G; Ruiz J
    Microb Pathog; 2021 Jun; 155():104907. PubMed ID: 33930424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media.
    Park MH; Kim SY; Roh EY; Lee HS
    Auris Nasus Larynx; 2017 Jun; 44(3):258-265. PubMed ID: 27461174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.
    Aiello D; Williams JD; Majgier-Baranowska H; Patel I; Peet NP; Huang J; Lory S; Bowlin TL; Moir DT
    Antimicrob Agents Chemother; 2010 May; 54(5):1988-99. PubMed ID: 20176902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yersinia pseudotuberculosis YopD mutants that genetically separate effector protein translocation from host membrane disruption.
    Adams W; Morgan J; Kwuan L; Auerbuch V
    Mol Microbiol; 2015 May; 96(4):764-78. PubMed ID: 25684661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Psychrotrophic Pseudomonas lundensis, a Non-
    Ravi K; Falkowski NR; Scales BS; Akulava VD; Valentovich LN; Huffnagle GB
    mBio; 2022 Feb; 13(1):e0386921. PubMed ID: 35189702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomonas aeruginosa Magnesium Transporter MgtE Inhibits Type III Secretion System Gene Expression by Stimulating
    Chakravarty S; Melton CN; Bailin A; Yahr TL; Anderson GG
    J Bacteriol; 2017 Dec; 199(23):. PubMed ID: 28847924
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel type III effectors in Pseudomonas aeruginosa.
    Burstein D; Satanower S; Simovitch M; Belnik Y; Zehavi M; Yerushalmi G; Ben-Aroya S; Pupko T; Banin E
    mBio; 2015 Mar; 6(2):e00161. PubMed ID: 25784698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased plasmid copy number is essential for Yersinia T3SS function and virulence.
    Wang H; Avican K; Fahlgren A; Erttmann SF; Nuss AM; Dersch P; Fallman M; Edgren T; Wolf-Watz H
    Science; 2016 Jul; 353(6298):492-5. PubMed ID: 27365311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of specific sequence motif of YopN of Yersinia pseudotuberculosis required for systemic infection.
    Bamyaci S; Nordfelth R; Forsberg Å
    Virulence; 2019 Dec; 10(1):10-25. PubMed ID: 30488778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-Labeling Enzyme Tags for Analyses of Translocation of Type III Secretion System Effector Proteins.
    Göser V; Kommnick C; Liss V; Hensel M
    mBio; 2019 Jun; 10(3):. PubMed ID: 31239375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System.
    Goldberg JB; Crisan CV; Luu JM
    Adv Exp Med Biol; 2022; 1386():257-280. PubMed ID: 36258075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutathione Activates Type III Secretion System Through Vfr in
    Zhang Y; Zhang C; Du X; Zhou Y; Kong W; Lau GW; Chen G; Kohli GS; Yang L; Wang T; Liang H
    Front Cell Infect Microbiol; 2019; 9():164. PubMed ID: 31157178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.
    Berube BJ; Murphy KR; Torhan MC; Bowlin NO; Williams JD; Bowlin TL; Moir DT; Hauser AR
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807906
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of host membrane pore formation by the Yersinia pseudotuberculosis type III secretion system on the macrophage innate immune response.
    Kwuan L; Adams W; Auerbuch V
    Infect Immun; 2013 Mar; 81(3):905-14. PubMed ID: 23297383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of Pseudomonas aeruginosa ExsA DNA-Binding Activity by N-Hydroxybenzimidazoles.
    Marsden AE; King JM; Spies MA; Kim OK; Yahr TL
    Antimicrob Agents Chemother; 2016 Feb; 60(2):766-76. PubMed ID: 26574012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A ParDE toxin-antitoxin system is responsible for the maintenance of the
    Schott S; Scheuer R; Ermoli F; Glatter T; Evguenieva-Hackenberg E; Diepold A
    Front Cell Infect Microbiol; 2023; 13():1166077. PubMed ID: 37228670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudomonas aeruginosa Can Diversify after Host Cell Invasion to Establish Multiple Intracellular Niches.
    Kumar NG; Nieto V; Kroken AR; Jedel E; Grosser MR; Hallsten ME; Mettrucio MME; Yahr TL; Evans DJ; Fleiszig SMJ
    mBio; 2022 Dec; 13(6):e0274222. PubMed ID: 36374039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components.
    Hotinger JA; Pendergrass HA; May AE
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33669653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and characterization of small-molecule inhibitors of Yop translocation in Yersinia pseudotuberculosis.
    Harmon DE; Davis AJ; Castillo C; Mecsas J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3241-54. PubMed ID: 20498321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.